Worldwide Innovative Networking Consortium

While the company reported an increase in revenues from biopharma partners, this gain was more than offset by lower consumable sales.

Illumina is the latest to join the consortium, which is focused on personalizing cancer care.

The algorithm may be able to rationally determine the three-drug strategy with the best chance of overcoming resistance and improving survival in advanced lung cancer patients.

Launched by the Institute Gustav Roussy in France and the University of Texas MD Anderson Cancer Center, the Worldwide Innovative Networking Consortium aims to help drugmakers change the way they develop drugs by focusing on treating diseases with common molecular features, rather than treating disease at an organ site.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.